


**A 25 Mainland Chinese cohort of patients with PURA-related  
neurodevelopmental disorders: clinical delineation and genotype–  
phenotype correlations**

Wei-qian Dai<sup>1</sup>, Yu Sun<sup>1</sup>, Yan-jie Fan<sup>1</sup>, Yan Gao<sup>1</sup>, Yong-kun Zhan<sup>1</sup>, Lili Wang<sup>1</sup>, Bing Xiao<sup>1</sup>,  
Wenjuan Qiu<sup>1</sup>, Xuefan Gu<sup>1</sup>, Kun Sun<sup>2\*</sup>, Yongguo Yu<sup>1\*</sup>, Na Xu<sup>1\*</sup>

<sup>1</sup>Department of Pediatric Endocrinology and Genetics, Xinhua Hospital Affiliated to Shanghai  
Jiao Tong University School of Medicine; Shanghai Institute for Pediatric Research, Shanghai,  
200092, China

<sup>2</sup>Center of Clinical Genetics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University  
School of Medicine; Shanghai, 200092, China

\* Equal contribution as co-corresponding author



**Supplementary Fig. S1:** The effects of *PURA* variants on protein structure. The representation of the structure of human *PURA* (GenBank: NP\_005850.1) was predicted by alphafold (The red arrow indicates the H-bonds). PUR-I domain, PUR-II domain and PUR-III domain is respectively shown in green, yellow and cyan. (A) The effects of loss-of-function variants on protein structure. (B) The effects of missense variants on protein structure.



**Supplementary Fig. S2:** Large areas of lightened skin pigmentation of patient 7 was shown.

Table S3. Summarization of *PURA* gene variants in 24 patients with PURA syndrome (including detailed ACMG classification)

Patient	Variant	Protein change	ACMG classification	Pathogenicity
P1	c.159dup	p.L54Afs*147	PM2+PVS1-Strong+PS2+PS4-Supporting+PP4(P)	Pathogenic
P2	c.42_43del	p.L15Gfs*185	PM2+PVS1-Strong +PS2-Moderate+PP4(LP)	Likely pathogenic
P3	c.159dup	p.L54Afs*147	PM2+PVS1-Strong+PS2+PS4-Supporting +PP4(P)	Pathogenic
P4	c.697_699del	p.F233del	PM2+PM4+PM6-Supporting+PS4+PP4 (P)	Pathogenic
P5	c.449delG	p.R150Pfs*75	PM2+PVS1-Strong +PS2+PP4(P)	Pathogenic
P6	c.159dup	p.L54Afs*147	PM2+PVS1-Strong+PM6+PS4-Supporting+PP4(P)	Pathogenic
P7	c.697_699del	p.F233del	PM2+PM4+PM6-Supporting+PP4+PS4 (P)	Pathogenic
P8	c.159dup	p.L54Afs*147	PM2+PVS1-Strong+PM6+PS4-Supporting+PP4(P)	Pathogenic
P9	c.692T>G	p.F231C	PM2+PM5+PM6-Supporting+PP4(LP)	Likely pathogenic
P10	c.575C>T	p.A192V	PM2+PM1+PM6-Supporting+PP4(LP)	Likely pathogenic
P11	c.458G>C	p.R153P	PM2+PM6-Supporting+PP4(VUS)	Uncertain significance
P12	c.531del	p.P178Lfs*47	PM2+PVS1-Strong +PS2+PP4(P)	Pathogenic
P13	c.10C>T	p.R4X	PM2+PVS1-Strong +PS2-Moderate+PP4(LP)	Likely Pathogenic
P14	c.583C>G	p.L195V	PM2+PM6-Supporting+PP4(VUS)	Uncertain significance
P15	c.865delC	p.R289fs*39	PM2+PVS1-Strong+PS2-Supporting(LP)	Likely pathogenic
P16	c.812T>C	p.F271S	PM2+PS2-Supporting+PP3(VUS)	Uncertain significance
P17	c.72delC	p.G25Afs*53	PM2+PVS1-Strong +PS2+PP4(P)	Pathogenic
P18	c.506G>C	p.R169P	PM2+PP3+PS2+PP4(LP)	Likely pathogenic
P19	c.697_699del	p.F233del	PM2+PM4+PM6-Supporting+PS4+PP4(P)	Pathogenic
P20	c.697_699del	p.F233del	PM2+PM4+PM6-Supporting+PS4+PP4(P)	Pathogenic
P21	c.218T>G	p.F73C	PM2+ PS2+PP4(LP)	Likely pathogenic
P22	c.550C>T	p.Q184Ter	PM2+PVS1-Strong +PM6-Supporting (LP)	Likely pathogenic
P23	c.149_156dup	p.G53Pfs*28	PM2+PVS1-Strong +PM6+PP4(LP)	Likely pathogenic

---

P24	c.430A>T	p.K144X	PM2+PVS1-Strong +PS2-Moderate(LP)	Likely pathogenic
-----	----------	---------	-----------------------------------	-------------------

---